Clarest Health, a leading personalized medication management provider, announced that it has acquired Remedi SeniorCare, giving Clarest the size and scale to lead the post-acute care market. The U.S. market for pharmacy care for the post-acute patient population is $5.7 billion, and the U.S. Rx fill market for medically complex patients is $115 billion, according to interviews, research and analysis from L.E.K. Financial terms of the deal were not disclosed.
Headquartered in Towson, Maryland, Remedi SeniorCare is a long-term and post-acute care pharmacy services provider. Renowned for its long-term care pharmacy services and proprietary medication management system PAXIT® and its customer portal, MyRemedi®, Remedi SeniorCare leads medication adherence in Skilled Nursing facilities and Assisted Living communities.
As a mission-driven pharmacy health expert, Clarest Health offers an end-to-end, patient-centered medication management solution to support patients in optimizing, accessing and adhering to their medication regimen.
“This is an exciting moment for us,” says Hammad Shah, CEO of Clarest Health. “By adding Remedi to our organization, we are uniquely positioned to transform post-acute pharmacy care for aging patients in the hospital, at home, in assisted living communities, and in skilled nursing facilities. Currently, there are many gaps in providing the best medication care to the aging population. We are committed to filling these gaps through technology-based medication optimization and fulfillment.”
According to data captured in the LevinPro HC database, this transaction represents the first specialty pharmacy acquisition of 2024. During 2023, there were 15 specialty pharmacy deals announced.
